Guillaume Cartron
Cartron, Guillaume
Cartron, Guillaume, 1966-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 69264965 (Personal)
Permalink: http://viaf.org/viaf/69264965
Preferred Forms
-
200 _ |
‡a
Cartron
‡b
Guillaume
-
100 1 _ ‡a Cartron, Guillaume
-
100 1 _
‡a
Cartron, Guillaume
-
100 1 _ ‡a Cartron, Guillaume
-
100 1 _
‡a
Cartron, Guillaume
-
100 1 _
‡a
Cartron, Guillaume,
‡d
1966-....
-
100 0 _
‡a
Guillaume Cartron
4xx's: Alternate Name Forms (4)
Works
| Title | Sources |
|---|---|
| Anémie en cancérologie, 2012: |
|
| Aspects cliniques et thérapeutiques des leucémies aiguës lymphoblastiques de l'enfant : à propos de 55 cas |
|
| Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. |
|
| Cell-specific targeting of interferon alpha activity. |
|
| Ciblage de l'activité de l'interféron alpha : de la preuve de concept à l'activité biologique |
|
| Les cibles de l'immunité |
|
| Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis |
|
| Citrobacter koseri cellulitis during anti-CD20 monoclonal antibody (ofatumumab) treatment for B-cell chronic lymphocytic leukaemia |
|
| Classifications et index pronostiques des hémopathies malignes |
|
| Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. |
|
| Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. |
|
| Clinical radioimmunotherapy--the role of radiobiology. |
|
| Comparison of EBV DNA viral load in whole blood, plasma, B-cells and B-cell culture supernatant |
|
| CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. |
|
| Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions |
|
| DNA repair in diffuse large B-cell lymphoma: a molecular portrait |
|
| Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases. |
|
| Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies |
|
| Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy |
|
| Efficacité et tolérance du MabCampath® dans la LLC-B en phase précoce de rechute après autogreffe |
|
| Efficacity and tolerance of alemtuzumab in B-CLL in early phase of relapse after autologous transplantation. |
|
| Etude fonctionnelle des formes oncogéniques de KIT : nouvelles stratégies d'inactivation de la signalisation oncogénique KIT |
|
| Etude quantitative et fonctionnelle du compartiment des progéniteurs primitifs après autogreffe de cellules souches hématopoïétiques chez l'homme |
|
| Évaluation externe et validation des modèles pharmacocinétiques de population du méthotrexate haute dose chez les patients adultes atteints d'hémopathies malignes lymphoïdes |
|
| Evaluation of a peptide ELISA for the detection of rituximab in serum. |
|
| Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies |
|
| Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche |
|
| Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma |
|
| FCGR3A polymorphism story: a new piece of the puzzle |
|
| First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study. |
|
| Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? |
|
| Frequency and differentiation capacity of circulating LTC-IC mobilized by G-CSF or GM-CSF following chemotherapy: a comparison with steady-state bone marrow and peripheral blood |
|
| From the bench to the bedside: ways to improve rituximab efficacy. |
|
| Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA |
|
| Histoire de la thérapie ciblée en cancérologie [Multimédia multisupport] |
|
| Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production |
|
| Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients With Hematological Cancers |
|
| Imagerie quantitative de bioluminescence appliquée à un modèle murin syngénique de lymphone exprimant le CD20 humain : analyses de l'influence du volume tumoral sur la réponse au rituximab, et de l'effet thérapeutique de neutrons et de nanoparticules chargées |
|
| Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients |
|
| [Implications of receptors for the Fc portion of IgG (FcgammaRs) in mechanism of action of therapeutic antibodies] |
|
| Increased T-cell activation and Th1 cytokine concentrations prior to the diagnosis of B-cell lymphoma in HIV infected patients |
|
| Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. |
|
| Kinetic and organization of granulocytes transfusion: a case report |
|
| A la recherche de facteurs de variabilité de réponse aux anticorps thérapeutiques : analyse des polymorphismes de FCGRT |
|
| Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks |
|
| Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) |
|
| Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. |
|
| Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow. |
|
| Lymphome plasmatique : analyse d'une cohorte de 109 patients |
|
| miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study |
|
| Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. |
|
| Molecular Analysis of clonal evolutions in hematological malignancies, including mutations of TP53 : consequences on therapeutic resistance and cancer progression. |
|
| Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment |
|
| New anti-CD20 monoclonal antibodies: which is the best? |
|
| Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study |
|
| Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). |
|
| Obinutuzumab in hematologic malignancies: lessons learned to date |
|
| Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study |
|
| Obinutuzumab: what is there to learn from clinical trials? |
|
| Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study |
|
| Pharmacokinetics of rituximab and its clinical use: thought for the best use? |
|
| A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies |
|
| Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. |
|
| Quantitative and qualitative analysis of primitive progenitor compartment after autologous stem cell transplantation in human. |
|
| Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. |
|
| Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. |
|
| Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial |
|
| Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. |
|
| Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis |
|
| Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. |
|
| Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. |
|
| Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines |
|
| Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma |
|
| Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. |
|
| Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism |
|
| T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells |
|
| Therapeutic interest and mechanisms of action of SUMOylation inhibition in non-promyelocytic acute myeloid leukemias. |
|
| Transcriptomic approach contribution in the physiopathology and treatment of hematological malignancies. |
|
| Treatment Response and Outcomes in Post-transplantation Lymphoproliferative Disease vs Lymphoma in Immunocompetent Patients |
|
| Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines |
|
| Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. |
|
| Visceral leishmaniasis. Persistence of parasites in lymph nodes after clinical cure |
|
